It depends on the standard you follow. As of September 2026, United Therapeutics Corporation (UTHR) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 15.4% / 30% · Interest income / Revenue 4.05% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 9.04% / 33% · Receivables / Mkt Cap (36m) 1.52% / 49% · Interest income / Revenue 4.05% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 9.04% / 33.33% · Receivables / Mkt Cap (24m) 1.52% / 33.33% · Interest income / Revenue 4.05% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 29.3% / 33.33% · Receivables / Avg Assets (4Q) 4.58% / 33.33% · Interest income / Revenue 4.05% / 5% | Pass |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 29.4% / 33.33% · (Cash+Recv) / Total Assets 34.4% / 33.33% · Interest income / Revenue 4.05% / 5% | Fail |
It depends on the standard you follow. As of September 2026, United Therapeutics Corporation (UTHR) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. United Therapeutics Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 4.05% of each dividend: United Therapeutics Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
United Therapeutics Corporation (NASDAQ: UTHR) is a Healthcare company (Biotechnology) with a market capitalization of $25.0B. The Maz Rating grades it against the other companies in its sector.
United Therapeutics Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $587.88, United Therapeutics Corporation trades at 20.6x trailing earnings, 7.9x sales and 4.0x book value, with an EV/EBITDA of 15.1. Over the last twelve months it generated about $3.2B of revenue and $1.2B of net income. It runs a gross margin of 86.3%, an operating margin of 41.5% and a net margin of 38.6%. It shows return on equity of 19.2%, return on invested capital of 16.8% and a free cash flow yield of 3.5%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 4.61. Over the past 52 weeks the share price ranged from $455.63 to $614.23, with a beta of 0.56.
United Therapeutics Corporation does not currently pay a dividend.
31 Wall Street analyst ratings cover the stock: 18 Buy, 12 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.